249 related articles for article (PubMed ID: 32782152)
1. Different mechanisms of cisplatin resistance development in human lung cancer cells.
Okamoto K; Saito Y; Narumi K; Furugen A; Iseki K; Kobayashi M
Biochem Biophys Res Commun; 2020 Oct; 530(4):745-750. PubMed ID: 32782152
[TBL] [Abstract][Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effects of non-steroidal anti-inflammatory drugs against cancer cells and cancer stem cells.
Okamoto K; Saito Y; Narumi K; Furugen A; Iseki K; Kobayashi M
Toxicol In Vitro; 2021 Aug; 74():105155. PubMed ID: 33785417
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
[TBL] [Abstract][Full Text] [Related]
5. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
6. [Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
He J; Song X; Yu L; Li J; Qiao Z; Jiu R; Yu B; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):625-9. PubMed ID: 25940289
[TBL] [Abstract][Full Text] [Related]
7. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
8. A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells.
Li XQ; Yue CW; Xu WH; Lü YH; Huang YJ; Tian P; Liu T
Biomed Pharmacother; 2020 Aug; 128():110322. PubMed ID: 32505822
[TBL] [Abstract][Full Text] [Related]
9. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
Zhang L; Liu X; Tang Z; Li X; Wang G
Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
[TBL] [Abstract][Full Text] [Related]
10. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells.
Horibe S; Kawauchi S; Tanahashi T; Sasaki N; Mizuno S; Rikitake Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):426-432. PubMed ID: 30448176
[TBL] [Abstract][Full Text] [Related]
11. Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets.
Cheng Q; Liao M; Hu H; Li H; Wu L
Cell Physiol Biochem; 2018; 47(1):279-292. PubMed ID: 29768255
[TBL] [Abstract][Full Text] [Related]
12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Cao L; Zhou X; Ding X; Gao D
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
15. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
16. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
17. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
18. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
